TB-500

Thymosin Beta-4 is a 43-amino-acid protein found in nearly every mammalian cell type, and in particularly high concentration in platelets and in wound fluid. TB-500 is a synthetic fragment reproducing the region of that protein — centred on the LKKTETQ motif — which binds monomeric G-actin.

Working with the fragment rather than the whole protein is a deliberate experimental choice. It isolates the actin-binding function from everything else the parent protein does, which makes any result easier to attribute.

Actin polymerisation is how a cell changes shape, and changing shape is how it moves. A molecule that sequesters G-actin therefore sits upstream of cell migration generally, rather than of any one tissue. That single mechanism is what connects the otherwise unrelated areas TB-500 turns up in:

• Endothelial cell migration, and the formation of new vessels in experimental tissue

• Keratinocyte and fibroblast movement in wound-closure assays

• Cardiac models, where Thymosin Beta-4 itself has a substantial literature following myocardial injury

• Corneal and dermal repair models, where migration rate is directly measurable

• Inflammatory signalling, reported as a secondary effect rather than a primary target

The property that most often decides its selection is that the fragment distributes through the circulation rather than remaining where it was introduced. Studies concerned with tissue remote from the administration site tend to use TB-500 for that reason, and studies concerned with a specific lesion tend not to.

BPC-157 is the standard comparator, and the two are combined in the Wolverine Stack precisely because their distribution profiles differ. GHK-Cu appears in the same connective-tissue literature through a different mechanism — copper transport and matrix gene expression rather than actin binding.